Literature DB >> 25687818

Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management.

Nauras Shuker1, Teun van Gelder2, Dennis A Hesselink3.   

Abstract

Tacrolimus (Tac) is widely used for the prevention of rejection after solid organ transplantation. Finding the optimal balance between effective Tac concentrations and toxicity is a challenge and requires therapeutic drug monitoring. In addition to the well-known inter-patient variability, the clinical use of Tac is also complicated by considerable intra-patient variability (IPV) in Tac exposure. Tac IPV is defined as the amount of fluctuation of whole-blood concentrations over a certain period of time during which the Tac dose remains unchanged. A high IPV in Tac exposure has recently been recognized as a strong risk factor for acute rejection and poor long-term kidney transplantation outcome. In addition to non-adherence, several other factors determine the magnitude of the IPV in Tac exposure. Quantification of IPV is easy and can be easily incorporated into everyday clinical practice as a tool for optimizing transplantation outcomes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25687818     DOI: 10.1016/j.trre.2015.01.002

Source DB:  PubMed          Journal:  Transplant Rev (Orlando)        ISSN: 0955-470X            Impact factor:   3.943


  47 in total

1.  Tacrolimus Variability: A Cause of Donor-Specific Anti-HLA Antibody Formation in Children.

Authors:  Gulsah Kaya Aksoy; Elif Comak; Mustafa Koyun; Halide Akbaş; Bahar Akkaya; Bülent Aydınlı; Fahri Uçar; Sema Akman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-02-08       Impact factor: 2.441

2.  Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients.

Authors:  Stephan R Seibert; David P Schladt; Baolin Wu; Weihua Guan; Casey Dorr; Rory P Remmel; Arthur J Matas; Roslyn B Mannon; Ajay K Israni; William S Oetting; Pamala A Jacobson
Journal:  Clin Transplant       Date:  2018-10-31       Impact factor: 2.863

Review 3.  Genetics of acute rejection after kidney transplantation.

Authors:  Casey R Dorr; William S Oetting; Pamala A Jacobson; Ajay K Israni
Journal:  Transpl Int       Date:  2017-11-08       Impact factor: 3.782

4.  Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.

Authors:  David J Taber; Zemin Su; James N Fleming; John W McGillicuddy; Maria A Posadas-Salas; Frank A Treiber; Derek Dubay; Titte R Srinivas; Patrick D Mauldin; William P Moran; Prabhakar K Baliga
Journal:  Transplantation       Date:  2017-12       Impact factor: 4.939

5.  Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device.

Authors:  Tom C Zwart; Sumit R M Gokoel; Paul J M van der Boog; Johan W de Fijter; Dina M Kweekel; Jesse J Swen; Henk-Jan Guchelaar; Dirk Jan A R Moes
Journal:  Br J Clin Pharmacol       Date:  2018-10-15       Impact factor: 4.335

6.  The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study.

Authors:  David J Taber; Zemin Su; James N Fleming; Nicole A Pilch; Thomas Morinelli; Patrick Mauldin; Derek Dubay
Journal:  Transpl Int       Date:  2018-09-16       Impact factor: 3.782

Review 7.  Population Pharmacokinetic Modelling and Bayesian Estimation of Tacrolimus Exposure: Is this Clinically Useful for Dosage Prediction Yet?

Authors:  Emily Brooks; Susan E Tett; Nicole M Isbel; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

Review 8.  Once-daily prolonged-release tacrolimus formulations for kidney transplantation: what the nephrologist needs to know.

Authors:  Giovanni Piotti; Elena Cremaschi; Umberto Maggiore
Journal:  J Nephrol       Date:  2016-05-20       Impact factor: 3.902

9.  Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients.

Authors:  Karmila Abu Bakar; Nor Asiah Mohamad; Zsolt Hodi; Tom McCulloch; Alun Williams; Martin Christian; Tim Key; Jon Jin Kim
Journal:  Pediatr Nephrol       Date:  2019-09-13       Impact factor: 3.714

Review 10.  Clinical aspects of tacrolimus use in paediatric renal transplant recipients.

Authors:  Agnieszka Prytuła; Teun van Gelder
Journal:  Pediatr Nephrol       Date:  2018-02-26       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.